Compass Pathways Phase 3 Psilocybin trial results - Psychedelic Stock down 50%?! Emergency podcast!
Human 3 with Brom and Sam24 Kesä 2025

Compass Pathways Phase 3 Psilocybin trial results - Psychedelic Stock down 50%?! Emergency podcast!

Compass Pathways ($CMPS) released an interim readout from their Phase 3 trial of Psilocybin (COMP360) for treatment resistant depression (TRD).


The data was positive and highly anticipated by the psychedelic community, but the stock dropped 50% on June 23rd. Brom Rector and Sam Tabone of XEIA Venture Partners react and comment in this emergency podcast.


We discuss:


(0:00) - what did the Compass Pathways data readout actually say


(12:00) - putting the Compass trial results into context vs SSRIs, Lexapro, Spravato and Ketamine


(19:00) - why Compass crashed


(24:00) - will Comp360 get FDA approval?


(26:00) - will COMP360 be commercially successful?


(30:00) - price targets for Compass Pathways $CMPS


(35:00) - will Compass get acquired?


(40:00) - are we bullish or bearish on Compass?


Learn more about Brom, Sam and XEIA at www.xeiavp.com

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(33)

Dave Messina - YC founder turned investor talks TechBio

Dave Messina - YC founder turned investor talks TechBio

Ever wondered what Pioneer Fund’s Future of Health Fund is excited about? Want to know how to impress Dave Messina? Are you curious about how different funds communicate and interact?Give a listen to ...

6 Heinä 1h 16min

$HIMS Q2 Results - our take as healthcare venture capitalists

$HIMS Q2 Results - our take as healthcare venture capitalists

Brom Rector and Sam Tabone from XEIA Venture Partners - a VC firm that invests in the future of human health, wellbeing and performance - discuss $HIMS Q2 results and the HIMS business more broadly. W...

5 Elo 20251h 24min

Investing in Psychedelic BioTech [August 2025 webinar replay]

Investing in Psychedelic BioTech [August 2025 webinar replay]

Watch the video recording on YouTube: https://youtu.be/BM6x59oMnKg?si=qF0xDvgUMvU60ctP2025 has been the start of a bull period for psychedelic medicine.​Psychedelic Biotechs like GH Research, Compass ...

30 Heinä 202558min

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

Compass and ATAI latest news + are Psychedelics BACK in 2025?!

The past few years have been rough for psychedelic and shroom stocks, but recent news from ATAI (and Recognify), Compass Pathways and GH Research + positive regulatory tailwinds from RFK and MAHA make...

29 Heinä 202516min

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Bryan Johnson's Neuralink competitor - with Kernel CEO Ryan Field

Ryan Field is the CEO of Kernel, a brain-computer interface company founded by Bryan Johnson. Kernel is a cutting edge, non-invasive BCI that uses fNIRS to image the brain. Imagine if getting an MRI w...

22 Heinä 20251h 33min

How to start a VC fund

How to start a VC fund

I interviewed Michael Huseby to learn about his life story and his new book: Fundamentals: Your Friendly Guide to Investment Funds and SyndicationsThis is a great listen for anyone interested in start...

15 Heinä 20251h 20min

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Beyond Neuralink - Investing in Brain Computer Interfaces [webinar replay]

Replay of our webinar on investing in brain computer interfaces. Join our upcoming July 30th event on investing in psychedelic biotech: psybio.org

12 Heinä 20251h 9min

Designing Novel Brain Drugs with Xylo Bio

Designing Novel Brain Drugs with Xylo Bio

Xylo is a biotech startup that is using computational methods to design novel brain drugs to treat mental health disorders and neurodegeneration. Many of their drug candidates are inspired by naturall...

8 Heinä 20251h